Transparency notification of The Capital Group Companies Inc.
Participation on July 24, 2013 (pursuant to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).
BRUSSELS, Belgium, 30 July 2013 – 18:30 (CET) – regulated information
Pursuant to Article 14 of the law of May 2, 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from The Capital Group Companies Inc. (having its registered offices at 333 South Hope Street, 55th Floor, Los Angeles, CA 90071, USA).
The Capital Group Companies Inc. has notified that, following a disposal of UCB shares with voting rights by its subsidiary Capital Research and Management Company, on
July 24, 2013, the 7.5%-threshold was fallen below.
The Capital Group Companies Inc. (taking into account the holding of its subsidiary Capital Research and Management Company) now owns 13,737,874 UCB shares with voting rights, representing 7.49% of the total number of UCB shares with voting rights (i.e., 183,427,152).
Holders of voting rights
Notification of May 21, 2013
Notification of July 24, 2013
# of voting rights
# of voting rights
% of voting rights
The Capital Group Companies Inc.
Capital Research and Management Company
According to the transparency notification, The Capital Group Companies Inc. is the holding company for several investment management subsidiaries, including Capital Research and Management Company, a 100% owned subsidiary of The Capital Group Companies Inc. Capital Research and Management Company is a U.S.-based investment adviser that manages the American Funds family of mutual funds. All shares subject to the transparency notification are owned by mutual funds managed by Capital Research and Management Company. Each fund has granted proxy voting authority to Capital Research and Management Company.
An updated overview of the UCB SA/NV large shareholdings is included in the corporate governance charter of UCB SA/NV, which is published on UCB SA/NV’s website.
UCB SA/NV – Allée de la Recherche, 60 – 1070 Brussels – RPM/RPR Brussels 0403.053.608
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, email@example.com
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
Stay up-to-date on the latest news and information from UCB